Breve descripción
The purpose of this study is to learn more about the safety, tolerability, and effectiveness of AZD2373 and to better understand AMKD and associated health problems.
Médico del ensayo / Coordinador del estudio
Philip Madonia
Estimated Enrollment
96
Estimated End Date
October, 2026
Trial is for people with
A diagnosis of Apolipoprotein L1 (APOL1)-Mediated Kidney Disease (AMKD) – this is checked via a blood sample during the Screening ...
Study Goal
AZD2373 leads to decrease in UACR in patients with AMKD who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes ...
What is involved for the patient?
During the Screening and Run-in period (16-weeks) patients will be asked to allow researchers access to their medical history and the ...
About the drug or intervention
AZD2373 is being developed as a potential treatment for AMKD. It works by decreasing the production of the APOL1 protein. AZD2373 does ...